מדינה: אירלנד
שפה: אנגלית
מקור: HPRA (Health Products Regulatory Authority)
DICLOFENAC EPOLAMINE
Novartis Consumer Health UK Limited
1.293 g Grams
Medicated Plaster
2006-03-31
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Flector Tissugel 140 mg medicated plaster 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 140 cm 2 (10 cm x 14 cm) of medicated plaster contains a total of 180 mg of diclofenac epolamine corresponding to 140 mg of diclofenac sodium (1% w/w). Excipients: methyl parahydroxybenzoate (E218): 14 mg propyl parahydroxybenzoate (E216): 7 mg propylene glycol: 420 mg Referred to amount per plaster. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Medicated plaster. White to pale yellow paste spread as a uniform layer onto unwoven support. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Local symptomatic treatment of pain in epicondylitis and ankle sprain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Cutaneous use only Posology Adults and adolescents 16 years and older - Symptomatic treatment of ankle sprains : 1 application a day - Symptomatic treatment of epicondylitis : 1 application morning and evening. Duration of administration Flector Tissugel is to be used for as short as possible depending on the indication: - Symptomatic treatment of ankle sprains : 3 days - Symptomatic treatment of epicondylitis : max. 14 days. If there is no improvement, during the recommended duration of treatment or symptoms worsen, a doctor should be consulted. Elderly This medication should be used with caution in elderly patients who are more prone to adverse events. See also Section 4.4. Children and adolescents below 16 years IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 28/10/2011_ _CRN 2107038_ _page number: 1_ There are insufficient data on efficacy and safety available for children and adolescents below 16 years of age (see al קרא את המסמך השלם